Jul 26 2012
In this post in the Center for Global Health Policy's "Science Speaks" blog, IAVI President and CEO Margaret McGlynn, AVAC Executive Director Mitchell Warren and UNAIDS Executive Director Michel Sidibe highlight the release of a report from the HIV Vaccine & Microbicides Resource Tracking Working Group, which "documents 2011 research investments in preventive and therapeutic HIV vaccines, cure research, microbicide development, pre-exposure prophylaxis (PrEP) and operations research to support implementation of such evidence-based interventions as the prevention of vertical transmission, voluntary medical male circumcision and the use of antiretroviral therapies for HIV prevention" (Barton, 7/23). In related news, in a post in USAID's "Impact" blog, McGlynn writes about recent advances that have "fueled optimism and lent a new momentum to the field of HIV vaccine" research and development (R&D) (7/24).
 This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
|
Increased coronary vessel wall thickness linked to heart dysfunction in asymptomatic HIV patients